Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: Results from a 52-week phase III trial

International Journal of COPD

Volumn 7, Issue , 2012, Pages 43-55

  Tashkin, Donald P ^a   Doherty, Dennis E ^b   Kerwin, Edward ^c   Matiz Bueno, Carlos E ^d   Knorr, Barbara ^e   Shekar, Tulin ^e   Banerjee, Sibabrata ^e   Staudinger, Heribert ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Clinical Research Institute of Southern Oregon   (United States)

^d UNIVERSIDAD EL BOSQUE   (Colombia)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease; Exacerbation; FEV 1; Inhaled corticosteroid; Spirometry

Indexed keywords

FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; PLACEBO;

ADULT; ARTICLE; BACKACHE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; INFLUENZA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SCORING SYSTEM; SMOKING; SPIROMETRY; THORAX PAIN; THRUSH; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADULT; AREA UNDER CURVE; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PREGNADIENEDIOLS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SMOKING; SPIROMETRY; TREATMENT OUTCOME;

EID: 84857087525     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S27319     Document Type: Article

References (36)

1. American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD. Available at: http://www.thoracic.org/clinical/copd-guidelines/resources/copddoc.pdf. Accessed July 26, 2011.
2. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available at: http://www.goldcopd.org/. Accessed July 21, 2011.
3. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363: 1128-1138.
4. Doherty DE. A review of the role of FEV1 in the COPD paradigm. COPD. 2008;5:310-318.
5. Buist S. COPD: a common disease that is preventable and treatable. Prim Care Respir J. 2006;15:7-9.
6. Anderson RN, Smith BL. Deaths: leading causes for 2002. Natl Vita Stat Rep. 2005;53: 1-89.
7. Kochanek KD, Zu JQ, Murphy SL. Deaths: Preliminary Data for 2009. Hyattsville, MD: National Center for Health Statistics; 2011.
8. Man SF, McAlister FA, Anthonisen NR, Sin DD. Contemporary management of chronic obstructive pulmonary disease: clinical applications. JAMA. 2003;290:2313-2316.
9. Mak JC, Hisada T, Salmon M, Barnes PJ, Chung KF. Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. Br J Pharmacol. 2002;135:987-996.
10. Mak JC, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest. 1995;96:99-106.
11. Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care. Clinical Guideline 12. National Institute for Clinical Excellence; 2010. Available at: guidance.nice.org.uk/CG101. Accessed December 31, 2011.
12. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179-191.
13. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax. 2007;62:938-943.
14. Ceylan E. Budesonide-formoterol (inhalation powder) in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:115-122.
15. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124:834-843.
16. Koser A, Westerman J, Sharma S, Emmett A, Crater GD. Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. Open Respir Med J. 2010;4:86-91.
17. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1084-1091.
18. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metereddose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69:549-565.
19. Sheth K, Wasserman RL, Lincourt WR, et al. Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: Performance and patient satisfaction. Int J Clin Pract. 2006;60:1218-1224.
20. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68: 1975-2000.
21. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax. 2005;60:301-304.
22. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J. 2002;19:936-943.
23. Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res. 2008;9:73.
24. Cazzola M, Centanni S, Regorda C, et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther. 2001;14:41-45.
25. Meltzer EO, Kuna P, Nolte H, Nayak AS, LaForce C. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J. August 4, 2011. [Epub ahead of print.]
26. Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc. 2010;31:269-279.
27. Weinstein SF, Corren J, Murphy K, Nolte H, White M. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc. 2010;31:280-289.
28. Maspero JF, Nolte H, Cherrez-Ojeda I. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma. 2010;47:1106-1115.
29. Smith C, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998;48:956-960.
30. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol. 2000;40:1227-1236.
31. Anderson GP. Long acting inhaled beta-adrenoceptor agonists the comparative pharmacology of formoterol and salmeterol. Agents Actions Suppl. 1993;43:253-269.
32. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145: 1321-1327.
33. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005; 2:75-79.
34. Celli BR, Tashkin DP, Rennard SI, McElhattan J, Martin UJ. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respir Med. 2011;105:1176-1188.
35. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:2407-2416.
36. Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol. 2004;93:439-446.